SKylaRk: Phase II study of Isa-KRD in newly diagnosed, transplant-eligible multiple myeloma

SKylaRk trial update: Isa-KRd in newly diagnosed, transplant-eligible multiple myelomaПодробнее

IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myelomaПодробнее

Case 2: Transplant-eligible patient with newly diagnosed myelomaПодробнее

Isatuximab with VRd in Pts with Newly Diagnosed Multiple Myeloma Non-Eligible for TransplantПодробнее

Isatuximab, Carfilzomib, Lenalidomide, and Dex (Isa-KRd) in Pts with High-Risk Newly Diagnosed MMПодробнее

Four-year follow-up of GMMG-CONCEPT: efficacy of Isa-KRd in high-risk newly diagnosed myelomaПодробнее

Long-term results of a Phase Ib trial of Isa-VRd in newly diagnosed transplant-ineligible myelomaПодробнее

GMMG-CONCEPT trial: Isa-KRd in high-risk newly diagnosed multiple myelomaПодробнее

Isatuximab, carfilzomib, lenalidomide and dexamethasone (Isa-KRd) in front-line treatment of hig...Подробнее

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma: the SKylaRk trialПодробнее

Addition of Isatuximab to RVd As Induction Therapy for Newly-Diagnosed, Transplant-Eligible MM PtsПодробнее

Can Isa-KRd achieve deep responses in high-risk NDMM, regardless of transplant eligibility?Подробнее

An update on GRIFFIN: D-RVd in patients with newly diagnosed multiple myelomaПодробнее

Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the random...Подробнее

Survival Analysis of Newly Diagnosed Transplant-Eligible Myeloma Pts in the Randomized Forte TrialПодробнее

Isatuximab + Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple MyelomaПодробнее

Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)Подробнее

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myelomaПодробнее

Depth of response to Isa-KRd in front-line treatment of high-risk multiple myelomaПодробнее